the reduced d.b.h.-activity after treatment with 2-bromo-alpha-ergocriptine may be explained by a pronounced antagonistic influence of 2-bromo-alpha-ergocriptine on the presynaptic dopamine receptors , suggesting that presynaptic dopaminergic receptors are involved in parkinson 's disease .
C0013030
dopamine
C0282151
dopaminergic